论文部分内容阅读
目的糖尿病血管并发症和炎症因子及氧化应激的关系密切,本文探讨前列地尔治疗对糖尿病下肢血管病变患者炎症因子和氧化应激的影响。方法选择杭州市富阳区第一人民医院内分泌科2014年7月—2016年6月收治的糖尿病下肢血管病变患者140例,根据随机数字法分为治疗组和对照组,对照组给予常规治疗,治疗组在常规治疗的基础上给予前列地尔治疗。比较2组患者治疗前后踝肱比值、临床症状评分、细胞因子和氧化应激水平指标。结果治疗前,2组踝肱比值、临床症状评分、细胞因子和氧化应激水平指标差异无统计学意义(P>0.05)。治疗后,治疗组踝肱比值、超氧化物歧化酶高于对照组(P<0.05),临床症状评分、8异前列腺素F2α、氧化低密度脂蛋白低于对照组(P<0.05),2组白细胞介素-10、白细胞介素-6、肿瘤坏死因子-α比较差异无统计学意义(P>0.05)。治疗前后比较,治疗组治疗后踝肱比值、超氧化物歧化酶高于治疗前(P<0.05),临床症状评分、8异前列腺素F2α、氧化低密度脂蛋白低于治疗前(P<0.05),白细胞介素-10、白细胞介素-6、肿瘤坏死因子-α治疗后和治疗前比较差异无统计学意义(P>0.05);对照组治疗后上述指标与治疗前差异均无统计学意义(P>0.05)。结论前列地尔能够改善糖尿病下肢血管病变的临床症状和下肢血流,降低患者体内氧化应激反应,但对体内炎性细胞因子影响不明显。
Objective Diabetic vascular complications and inflammatory factors and oxidative stress are closely related, this article discusses the alprostadil treatment of diabetic patients with lower extremity vascular disease inflammatory cytokines and oxidative stress. Methods 140 cases of diabetic lower extremity vascular disease were treated in Department of Endocrinology, First People’s Hospital of Fuyang District, Hangzhou from July 2014 to June 2016. The patients were divided into treatment group and control group according to random number method. The control group was given routine treatment and treatment The group was given alprostadil on a regular basis. The ankle-brachial ratio, clinical symptom scores, cytokines and oxidative stress were compared between the two groups before and after treatment. Results Before treatment, there was no significant difference in the ankle-brachial ratio, clinical symptom score, cytokine and oxidative stress between the two groups (P> 0.05). After treatment, the ankle-brachial ratio and superoxide dismutase in the treatment group were significantly higher than those in the control group (P <0.05). The scores of clinical symptoms, 8 iso-prostaglandin F2α and oxidized low density lipoprotein were lower than those in the control group (P <0.05) There were no significant differences in the levels of interleukin-10, interleukin-6 and tumor necrosis factor-α (P> 0.05). Before and after treatment, the ankle-brachial ratio and superoxide dismutase (SOD) in the treatment group were significantly higher than those before treatment (P <0.05). The scores of clinical symptoms, 8 iso-prostaglandin F2α and oxidized low density lipoprotein ), Interleukin-10, interleukin-6 and tumor necrosis factor-alpha had no significant difference between before treatment and after treatment (P> 0.05). There was no significant difference between the control group and before treatment Significance (P> 0.05). Conclusion Alprostadil can improve the clinical symptoms of lower extremity vascular disease and lower extremity blood flow in diabetic patients, and reduce the oxidative stress response in patients. However, it has no obvious effect on inflammatory cytokines in vivo.